Clonal Hematopoiesis
Conditions
Brief summary
This study will investigate the association between clonal hematopoiesis and other conditions. Clonal hematopoiesis (CH) refers to the mutations in a person's stem cells which commonly affect people as they get older. These mutations have notably been linked to increased risk of certain cancers as well as increased risk of heart disease.
Detailed description
Objectives: * To develop the CHIVE Registry with CH patients or patients with elevated risk for CH in order to better characterize associated clinical outcomes and co-morbidities in these populations * To improve understanding of cardiovascular phenotypes and risk of patients with known Clonal Hematopoiesis of indeterminate potential (CHIP) or Clonal Cytopenias of undetermined significance (CCUS) * To investigate prognostic significance of CH mutations for the development hematologic malignancies * To generate a CHIVE Biorepository to acquire patient samples to study the natural history of CH, and to make available to CH investigators.
Interventions
OTHERBlood collection
Blood will be taken from participants already undergoing blood collection
OTHERSaliva collection
Undergo saliva collection
Bone marrow will be taken from participants already undergoing bone marrow collection
Sponsors
Vanderbilt-Ingram Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient greater than or equal to 18 years old at time of consent * Able to provide informed consent * Idiopathic cytopenia (ICUS) or idiopathic cytoses (elevated blood counts without disease or explanation); clonal cytopenia of undetermined significance (CCUS), clonal hematopoiesis of indeterminate potential (CHIP) or individuals at higher risk for clonal hematopoiesis (ex. patients with known diagnosis of solid tumors or cardiovascular disease)
Exclusion criteria
* Unable to provide consent * Diagnosis of active hematologic malignancy. For example, a diagnosis of CMML, AML, MDS, MPN; History of hematologic malignancy is NOT exclusionary if in complete remission (e.g. previous myeloma or lymphoma)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CHIVE Registry | Up to approximately 120 months | Aggregate data will be utilized to better understand the association between clonal hematopoiesis and other conditions |
| CHIVE Biorepository | Up to approximately 120 months | Number of biological samples collected and stored (Blood, saliva, bone marrow) for future studies. |
Countries
United States
Contacts
Primary ContactVanderbilt-Ingram Services for Timely Access
Outcome results
None listed